Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen
- PMID: 15964291
- DOI: 10.1016/j.contraception.2004.12.015
Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen
Abstract
Objectives: This trial tested the hypothesis that menstrually signaled use of contraceptive vaginal rings ("rings") releasing low-dose combinations of Nestorone (NES) and ethinyl estradiol (EE) would reliably suppress luteal activity and ovulation, and prevent unintended pregnancy, while controlling the incidence of menstrual bleeding episodes and bleeding days.
Methods: Nestorone/ethinyl estradiol rings releasing 50/10, 50/20 and 150/15 mug/day were studied through 6 months. A ring was to be used continuously, until its removal was signaled by menstrual bleeding. Reinsertion was required 96 h after removal. Serum for NES, EE and progesterone were collected and assayed, and vaginal ultrasound scans were performed in three 5-week periods to examine luteal activity, follicular growth, ovulation and their correlates. In 10 subjects using the 150/15 ring, six samples were drawn in the 24-h period after ring removal to examine serum levels of NES and EE.
Results: One hundred sixty subjects at three doses provided blood samples. Median serum concentrations of NES and EE demonstrated dose ratios slightly below the nominal dose ratios expected. Serum NES concentrations declined 19-22% from weeks 3 to 25. Changes in EE levels depended on dose. Nestorone levels fell 81% by 24 h after ring removal and EE levels fell by 50%. Luteal activity was completely suppressed in 94-95% of cycles and in 90% of subjects. Three pregnancies occurred in subjects participating in this serum sampling study.
Conclusion: Satisfactory serum levels of NES and EE, and a high level of ovulation suppression were achieved. Irregular ring use, however, permitted pregnancies to occur.
Similar articles
-
Clinical performance and menstrual bleeding patterns with three dosage combinations of a Nestorone progestogen/ethinyl estradiol contraceptive vaginal ring used on a bleeding-signaled regimen.Contraception. 2005 Jul;72(1):46-52. doi: 10.1016/j.contraception.2004.12.014. Contraception. 2005. PMID: 15964292 Clinical Trial.
-
Contraceptive vaginal rings releasing Nestorone and ethinylestradiol: a 1-year dose-finding trial.Contraception. 2005 Feb;71(2):122-9. doi: 10.1016/j.contraception.2004.08.010. Contraception. 2005. PMID: 15707562 Clinical Trial.
-
A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol.Contraception. 1999 May;59(5):305-10. doi: 10.1016/s0010-7824(99)00036-0. Contraception. 1999. PMID: 10494484 Clinical Trial.
-
Complete and robust ovulation inhibition with NuvaRing.Eur J Contracept Reprod Health Care. 2002 Dec;7 Suppl 2:13-8; discussion 37-9. Eur J Contracept Reprod Health Care. 2002. PMID: 12659397 Review.
-
Lower hormone dosage with improved cycle control.Eur J Contracept Reprod Health Care. 2002 Dec;7 Suppl 2:25-30; discussion 37-9. Eur J Contracept Reprod Health Care. 2002. PMID: 12659399 Review.
Cited by
-
Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women.Contraception. 2012 May;85(5):480-8. doi: 10.1016/j.contraception.2011.10.003. Epub 2011 Dec 15. Contraception. 2012. PMID: 22176795 Free PMC article. Clinical Trial.
-
Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.Pharmacol Ther. 2021 Jun;222:107789. doi: 10.1016/j.pharmthera.2020.107789. Epub 2020 Dec 13. Pharmacol Ther. 2021. PMID: 33316287 Free PMC article. Review.
-
Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception.Cochrane Database Syst Rev. 2014 Jul 29;2014(7):CD004695. doi: 10.1002/14651858.CD004695.pub3. Cochrane Database Syst Rev. 2014. PMID: 25072731 Free PMC article.
-
Vaginal rings for delivery of HIV microbicides.Int J Womens Health. 2012;4:595-605. doi: 10.2147/IJWH.S36282. Epub 2012 Nov 20. Int J Womens Health. 2012. PMID: 23204872 Free PMC article.
-
Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: pharmacokinetics from a dose-finding study.Contraception. 2018 May;97(5):422-427. doi: 10.1016/j.contraception.2018.01.012. Epub 2018 Feb 2. Contraception. 2018. PMID: 29409834 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical